Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.14 |
52 Week High | US$11.92 |
52 Week Low | US$4.77 |
Beta | 0.26 |
11 Month Change | -9.35% |
3 Month Change | -15.88% |
1 Year Change | -28.11% |
33 Year Change | -45.44% |
5 Year Change | 15.51% |
Change since IPO | -95.47% |
Recent News & Updates
Recent updates
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 01Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?
Mar 02Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?
Jan 26Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth
Dec 22Fennec Pharmaceuticals EPS misses by $0.05
Nov 16Fennec Pharmaceuticals: The Compensation Is What's Missing
Nov 05Shareholder Returns
FENC | US Biotechs | US Market | |
---|---|---|---|
7D | -2.8% | -3.8% | 1.8% |
1Y | -28.1% | 16.5% | 31.9% |
Return vs Industry: FENC underperformed the US Biotechs industry which returned 16.5% over the past year.
Return vs Market: FENC underperformed the US Market which returned 31.9% over the past year.
Price Volatility
FENC volatility | |
---|---|
FENC Average Weekly Movement | 7.3% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FENC's share price has been volatile over the past 3 months.
Volatility Over Time: FENC's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 29 | Rosty Raykov | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
FENC fundamental statistics | |
---|---|
Market cap | US$132.69m |
Earnings (TTM) | US$2.74m |
Revenue (TTM) | US$48.89m |
51.4x
P/E Ratio2.9x
P/S RatioIs FENC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FENC income statement (TTM) | |
---|---|
Revenue | US$48.89m |
Cost of Revenue | US$2.17m |
Gross Profit | US$46.72m |
Other Expenses | US$43.98m |
Earnings | US$2.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.10 |
Gross Margin | 95.55% |
Net Profit Margin | 5.59% |
Debt/Equity Ratio | -2,341.6% |
How did FENC perform over the long term?
See historical performance and comparison